A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Jazz Pharmaceuticals
- Study ID
- NCT07233239
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Focal Seizures
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- CBD-OS — DRUGStarting dose of CBD-OS will be administered as per the approved local product label
Study Details
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Key Dates
- Start date
- Nov 26, 2025
- Status verified
- Jun 2026
- Primary completion
- Nov 29, 2027
- Completion
- Nov 29, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CBD-OSParticipants who will receive open-label CBD-OS.
Primary Outcome Measure
Percent change in countable focal seizure frequency compared to baseline [ Time Frame: Baseline up to 16 weeks ]
Central Contacts
- Clinical Trial Disclosure & Transparency215-832-3750